Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy

J Infect Dis. 2001 Oct 15;184(8):1073-7. doi: 10.1086/323599. Epub 2001 Sep 13.


This study compared plasma bioavailable interleukin (IL)-6 levels in 3 groups: human immunodeficiency virus (HIV)-infected patients who had a human herpesvirus (HHV)-associated immune restoration disease (IRD) during highly active antiretroviral therapy (HAART); patients who experienced an IRD initiated by Mycobacterium avium complex, hepatitis C virus, or human papillomavirus; and control patients who had uneventful immune reconstitution. Total IL-6, soluble IL-6 receptor (sIL-6R), and soluble gp130 were measured by ELISA, and levels of free IL-6 and sIL-6/IL-6R complex were modeled mathematically. Persons who had an HHV-associated IRD had increased plasma bioavailable IL-6 before HAART, compared with patients who experienced a non-HHV-associated IRD and with control patients, and their plasma bioavailable IL-6 increased progressively over 3-4 years of treatment. Increased IL-6 production may be a feature of HAART-induced restoration of immune responses to HHV infections and may have long-term immunopathologic consequences.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiretroviral Therapy, Highly Active*
  • Biological Availability
  • Databases as Topic
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • Hepatitis C / complications
  • Herpes Simplex / immunology*
  • Humans
  • Interleukin-6 / blood
  • Interleukin-6 / pharmacokinetics*
  • Male
  • Mycobacterium avium Complex
  • Mycobacterium avium-intracellulare Infection / complications
  • Papillomaviridae
  • Papillomavirus Infections / complications
  • Receptors, Interleukin-6 / blood
  • Retrospective Studies
  • Tumor Virus Infections / complications


  • Interleukin-6
  • Receptors, Interleukin-6